Download PDF
Clin Colon Rectal Surg 2010; 23(4): 227-238
DOI: 10.1055/s-0030-1268249
© Thieme Medical Publishers

Pros and Cons of Medical Management of Ulcerative Colitis

Udayakumar Navaneethan1 , Bo Shen1
  • 1Center for Inflammatory Bowel Disease, Digestive Disease Institute, Cleveland Clinic, Cleveland, Ohio
Further Information

Publication History

Publication Date:
07 December 2010 (online)

    Permissions and Reprints

ABSTRACT

Ulcerative colitis (UC) is a chronic inflammatory disease characterized by diffuse mucosal inflammation limited to the colon and rectum. Although a complete medical cure may not be possible, UC can be treated with medications that induce and maintain remission. The medical management of this disease continues to evolve with a goal to avoid colectomy and ultimately alter the natural history of UC. Emergence of antitumor necrosis factor-α (TNF-α) agents has expanded the medical armamentarium. 5-Aminosalicylates continue to be used in mild to moderate UC and corticosteroids are mainly used for induction of remission with immunomodulators (6-mercaptopurine/azathiopurine/methotrexate) being applied as steroid-sparing agents for maintenance therapy. Infliximab has been approved by the U.S. Food and Drug Administration and used in the treatment of moderate to severe UC; nevertheless, its use may be associated with significant adverse effects and have a negative impact on the postoperative course should the patients undergo restorative proctocolectomy. In addition, there is always a concern about patients' compliance to medical therapy, cost of medications, and risk for UC-associated dysplasia. The authors discuss the pros and cons of medications used in the treatment of UC.

KEYWORDS

Inflammatory bowel disease - ulcerative colitis - medical treatment - risks and benefits

REFERENCES

  • 1 Meyers S, Janowitz H D. The “natural history” of ulcerative colitis: an analysis of the placebo response.  J Clin Gastroenterol. 1989;  11(1) 33-37
    CrossrefPubMedGoogle Scholar
  • 2 Loftus Jr E V, Silverstein M D, Sandborn W J, Tremaine W J, Harmsen W S, Zinsmeister A R. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival.  Gut. 2000;  46(3) 336-343
    CrossrefPubMedGoogle Scholar
  • 3 Kappelman M D, Rifas-Shiman S L, Kleinman K et al.. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States.  Clin Gastroenterol Hepatol. 2007;  5(12) 1424-1429
    CrossrefPubMedGoogle Scholar
  • 4 Loftus C G, Loftus Jr E V, Harmsen W S et al.. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000.  Inflamm Bowel Dis. 2007;  13(3) 254-261
    CrossrefPubMedGoogle Scholar
  • 5 Herrinton L J, Liu L, Lewis J D, Griffin P M, Allison J. Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996-2002.  Am J Gastroenterol. 2008;  103(8) 1998-2006
    CrossrefPubMedGoogle Scholar
  • 6 Herrinton L J, Liu L, Lafata J E et al.. Estimation of the period prevalence of inflammatory bowel disease among nine health plans using computerized diagnoses and outpatient pharmacy dispensings.  Inflamm Bowel Dis. 2007;  13(4) 451-461
    CrossrefPubMedGoogle Scholar
  • 7 Sonnenberg A, Chang J. Time trends of physician visits for Crohn's disease and ulcerative colitis in the United States, 1960-2006.  Inflamm Bowel Dis. 2008;  14(2) 249-252
    CrossrefPubMedGoogle Scholar
  • 8 Nguyen G C, Tuskey A, Dassopoulos T, Harris M L, Brant S R. Rising hospitalization rates for inflammatory bowel disease in the United States between 1998 and 2004.  Inflamm Bowel Dis. 2007;  13(12) 1529-1535
    CrossrefPubMedGoogle Scholar
  • 9 Kappelman M D, Rifas-Shiman S L, Porter C Q et al.. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults.  Gastroenterology. 2008;  135(6) 1907-1913
    CrossrefPubMedGoogle Scholar
  • 10 Edwards F C, Truelove S C. The course and prognosis of ulcerative colitis.  Gut. 1963;  4 299-315
    CrossrefPubMedGoogle Scholar
  • 11 Moum B, Vatn M H, Ekbom A Southeastern Norway IBD Study Group of Gastroenterologists et al. Incidence of inflammatory bowel disease in southeastern Norway: evaluation of methods after 1 year of registration.  Digestion. 1995;  56(5) 377-381
    CrossrefPubMedGoogle Scholar
  • 12 Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years.  Gastroenterology. 1994;  107(1) 3-11
    PubMedGoogle Scholar
  • 13 Langholz E, Munkholm P, Davidsen M, Nielsen O H, Binder V. Changes in extent of ulcerative colitis: a study on the course and prognostic factors.  Scand J Gastroenterol. 1996;  31(3) 260-266
    CrossrefPubMedGoogle Scholar
  • 14 Sandborn W J, Rutgeerts P, Feagan B G et al.. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab.  Gastroenterology. 2009;  137(4) 1250-1260 quiz 1520
    CrossrefPubMedGoogle Scholar
  • 15 Sutherland L, Macdonald J K. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.  Cochrane Database Syst Rev. 2006;  (2) CD000543
    PubMedGoogle Scholar
  • 16 Carter M J, Lobo A J, Travis S P. IBD Section, British Society of Gastroenterology . Guidelines for the management of inflammatory bowel disease in adults.  Gut. 2004;  53(Suppl 5) V1-V16
    CrossrefPubMedGoogle Scholar
  • 17 Lichtenstein G R, Kamm M A. Review article: 5-aminosalicylate formulations for the treatment of ulcerative colitis—methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosa.  Aliment Pharmacol Ther. 2008;  28(6) 663-673
    CrossrefPubMedGoogle Scholar
  • 18 Lichtenstein G R, Kamm M A, Sandborn W J, Lyne A, Joseph R E. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.  Aliment Pharmacol Ther. 2008;  27(11) 1094-1102
    CrossrefPubMedGoogle Scholar
  • 19 Rao S S, Dundas S A, Holdsworth C D, Cann P A, Palmer K R, Corbett C L. Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study.  Gut. 1989;  30(5) 675-679
    CrossrefPubMedGoogle Scholar
  • 20 Dick A P, Grayson M J, Carpenter R G, Petrie A. Controlled trial of sulphasalazine in the treatment of ulcerative colitis.  Gut. 1964;  5 437-442
    CrossrefPubMedGoogle Scholar
  • 21 Nikfar S, Rahimi R, Rezaie A, Abdollahi M. A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis.  Dig Dis Sci. 2009;  54(6) 1157-1170
    CrossrefPubMedGoogle Scholar
  • 22 Marshall J K, Irvine E J. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis.  Am J Gastroenterol. 2000;  95(7) 1628-1636
    CrossrefPubMedGoogle Scholar
  • 23 Lee F I, Jewell D P, Mani V et al.. A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis.  Gut. 1996;  38(2) 229-233
    CrossrefPubMedGoogle Scholar
  • 24 Regueiro M, Loftus Jr E V, Steinhart A H, Cohen R D. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials.  Inflamm Bowel Dis. 2006;  12(10) 979-994
    CrossrefPubMedGoogle Scholar
  • 25 Safdi M, DeMicco M, Sninsky C et al.. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis.  Am J Gastroenterol. 1997;  92(10) 1867-1871
    PubMedGoogle Scholar
  • 26 Moss A C, Peppercorn M A. The risks and the benefits of mesalazine as a treatment for ulcerative colitis.  Expert Opin Drug Saf. 2007;  6(2) 99-107
    CrossrefPubMedGoogle Scholar
  • 27 Hanauer S B, Sandborn W J, Dallaire C et al.. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial.  Can J Gastroenterol. 2007;  21(12) 827-834
    PubMedGoogle Scholar
  • 28 Kamm M A, Sandborn W J, Gassull M et al.. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.  Gastroenterology. 2007;  132(1) 66-75 quiz 432-433
    CrossrefPubMedGoogle Scholar
  • 29 Lichtenstein G R, Kamm M A, Boddu P et al.. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.  Clin Gastroenterol Hepatol. 2007;  5(1) 95-102
    CrossrefPubMedGoogle Scholar
  • 30 Sandborn W J, Kamm M A, Lichtenstein G R, Lyne A, Butler T, Joseph R E. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials.  Aliment Pharmacol Ther. 2007;  26(2) 205-215
    CrossrefPubMedGoogle Scholar
  • 31 Marteau P, Probert C S, Lindgren S et al.. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.  Gut. 2005;  54(7) 960-965
    CrossrefPubMedGoogle Scholar
  • 32 Kamm M A, Lichtenstein G R, Sandborn W J et al.. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis.  Gut. 2008;  57(7) 893-902
    CrossrefPubMedGoogle Scholar
  • 33 Kruis W, Kiudelis G, Rácz I International Salofalk OD Study Group et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial.  Gut. 2009;  58(2) 233-240
    CrossrefPubMedGoogle Scholar
  • 34 Kruis W, Jonaitis L, Pokrotnieks J et al.. Once daily 3 g mesalamine is the optimal dose for maintaining clinical remission in ulcerative colitis: a double-blind, double-dummy, randomized, controlled, dose ranging study.  Gastroenterology. 2008;  134(Suppl 1) A489
    PubMedGoogle Scholar
  • 35 Prescribing information for Apriso (extended release mesalamine). Morrisville, NC; Salix Pharmaceuticals, Inc 2009
    Google Scholar
  • 36 Velayos F S, Terdiman J P, Walsh J M. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies.  Am J Gastroenterol. 2005;  100(6) 1345-1353
    CrossrefPubMedGoogle Scholar
  • 37 Levine J S, Burakoff R. Chemoprophylaxis of colorectal cancer in inflammatory bowel disease: current concepts.  Inflamm Bowel Dis. 2007;  13(10) 1293-1298
    CrossrefPubMedGoogle Scholar
  • 38 James S L, Irving P M, Gearry R B, Gibson P R. Management of distal ulcerative colitis: frequently asked questions analysis.  Intern Med J. 2008;  38(2) 114-119
    CrossrefPubMedGoogle Scholar
  • 39 Lémann M, Galian A, Rutgeerts P et al.. Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis.  Aliment Pharmacol Ther. 1995;  9(5) 557-562
    CrossrefPubMedGoogle Scholar
  • 40 Faubion Jr W A, Loftus Jr E V, Harmsen W S, Zinsmeister A R, Sandborn W J. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study.  Gastroenterology. 2001;  121(2) 255-260
    CrossrefPubMedGoogle Scholar
  • 41 Truelove S C, Willoughby C P, Lee E G, Kettlewell M G. Further experience in the treatment of severe attacks of ulcerative colitis.  Lancet. 1978;  2(8099) 1086-1088
    PubMedGoogle Scholar
  • 42 Ng S C, Kamm M A. Therapeutic strategies for the management of ulcerative colitis.  Inflamm Bowel Dis. 2009;  15(6) 935-950
    CrossrefPubMedGoogle Scholar
  • 43 Löfberg R, Danielsson A, Suhr O et al.. Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis.  Gastroenterology. 1996;  110(6) 1713-1718
    CrossrefPubMedGoogle Scholar
  • 44 Pearson D C, May G R, Fick G H, Sutherland L R. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis.  Ann Intern Med. 1995;  123(2) 132-142
    CrossrefPubMedGoogle Scholar
  • 45 Black A J, McLeod H L, Capell H A et al.. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine.  Ann Intern Med. 1998;  129(9) 716-718
    PubMedGoogle Scholar
  • 46 Snow J L, Gibson L E. A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologic patients.  J Am Acad Dermatol. 1995;  32(1) 114-116
    CrossrefPubMedGoogle Scholar
  • 47 Hawthorne A B, Logan R F, Hawkey C J et al.. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis.  BMJ. 1992;  305(6844) 20-22
    CrossrefPubMedGoogle Scholar
  • 48 Adler D J, Korelitz B I. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis.  Am J Gastroenterol. 1990;  85(6) 717-722
    PubMedGoogle Scholar
  • 49 George J, Present D H, Pou R, Bodian C, Rubin P H. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine.  Am J Gastroenterol. 1996;  91(9) 1711-1714
    PubMedGoogle Scholar
  • 50 Ardizzone S, Molteni P, Imbesi V, Bollani S, Bianchi Porro G, Molteni F. Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis.  J Clin Gastroenterol. 1997;  25(1) 330-333
    CrossrefPubMedGoogle Scholar
  • 51 Lobo A J, Foster P N, Burke D A, Johnston D, Axon A T. The role of azathioprine in the management of ulcerative colitis.  Dis Colon Rectum. 1990;  33(5) 374-377
    CrossrefPubMedGoogle Scholar
  • 52 Karoui S, Djebbi S, Belkhodja A, Boubaker J, Filali A. [Maintenance therapy by azathioprine after successful treatment by intravenous corticosteroid in acute severe colitis. An open prospective study].  Tunis Med. 2008;  86(4) 322-327
    PubMedGoogle Scholar
  • 53 Timmer A, McDonald J W, Macdonald J K. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis.  Cochrane Database Syst Rev. 2007;  (1) CD000478
    PubMedGoogle Scholar
  • 54 Mantzaris G J, Sfakianakis M, Archavlis E et al.. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis.  Am J Gastroenterol. 2004;  99(6) 1122-1128
    CrossrefPubMedGoogle Scholar
  • 55 Gisbert J P, Linares P M, McNicholl A G, Maté J, Gomollón F. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis.  Aliment Pharmacol Ther. 2009;  30(2) 126-137
    CrossrefPubMedGoogle Scholar
  • 56 Lichtenstein G R, Abreu M T, Cohen R, Tremaine W. American Gastroenterological Association . American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease.  Gastroenterology. 2006;  130(3) 940-987
    CrossrefPubMedGoogle Scholar
  • 57 Lichtiger S, Present D H, Kornbluth A et al.. Cyclosporine in severe ulcerative colitis refractory to steroid therapy.  N Engl J Med. 1994;  330(26) 1841-1845
    CrossrefPubMedGoogle Scholar
  • 58 D'Haens G, Lemmens L, Geboes K et al.. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis.  Gastroenterology. 2001;  120(6) 1323-1329
    CrossrefPubMedGoogle Scholar
  • 59 Svavoni F, Bonassi U, Bagnolo F et al.. Effectiveness of cyclosporine (CsA) in the treatment of refractory ulcerative colitis (UC).  Gastroenterology. 1998;  114 A1096
    PubMedGoogle Scholar
  • 60 Van Assche G, D'Haens G, Noman M et al.. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis.  Gastroenterology. 2003;  125(4) 1025-1031
    CrossrefPubMedGoogle Scholar
  • 61 Moskovitz D N, Van Assche G, Maenhout B et al.. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis.  Clin Gastroenterol Hepatol. 2006;  4(6) 760-765
    CrossrefPubMedGoogle Scholar
  • 62 Shibolet O, Regushevskaya E, Brezis M, Soares-Weiser K. Cyclosporine A for induction of remission in severe ulcerative colitis.  Cochrane Database Syst Rev. 2005;  (1) CD004277
    PubMedGoogle Scholar
  • 63 Shah S B, Parekh N K, Hanauer S B et al.. Intravenous cyclosporine in severe steroid-refractory ulcerative colitis: long term follow-up.  Gastroenterology. 2008;  134(Suppl 1) 133
    PubMedGoogle Scholar
  • 64 Cohen R D, Brodsky A L, Hanauer S B. A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin.  Inflamm Bowel Dis. 1999;  5(1) 1-10
    CrossrefPubMedGoogle Scholar
  • 65 Arts J, D'Haens G, Zeegers M et al.. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis.  Inflamm Bowel Dis. 2004;  10(2) 73-78
    CrossrefPubMedGoogle Scholar
  • 66 Rayner C K, McCormack G, Emmanuel A V, Kamm M A. Long-term results of low-dose intravenous cyclosporin for acute severe ulcerative colitis.  Aliment Pharmacol Ther. 2003;  18(3) 303-308
    CrossrefPubMedGoogle Scholar
  • 67 Chey W Y. Infliximab for patients with refractory ulcerative colitis.  Inflamm Bowel Dis. 2001;  7(Suppl 1) S30-S33
    CrossrefPubMedGoogle Scholar
  • 68 Chey W Y, Hussain A, Ryan C, Potter G D, Shah A. Infliximab for refractory ulcerative colitis.  Am J Gastroenterol. 2001;  96(8) 2373-2381
    CrossrefPubMedGoogle Scholar
  • 69 Kaser A, Mairinger T, Vogel W, Tilg H. Infliximab in severe steroid-refractory ulcerative colitis: a pilot study.  Wien Klin Wochenschr. 2001;  113(23-24) 930-933
    PubMedGoogle Scholar
  • 70 Su C, Salzberg B A, Lewis J D et al.. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis.  Am J Gastroenterol. 2002;  97(10) 2577-2584
    CrossrefPubMedGoogle Scholar
  • 71 Gornet J M, Couve S, Hassani Z et al.. Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study.  Aliment Pharmacol Ther. 2003;  18(2) 175-181
    CrossrefPubMedGoogle Scholar
  • 72 Sands B E, Tremaine W J, Sandborn W J et al.. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.  Inflamm Bowel Dis. 2001;  7(2) 83-88
    CrossrefPubMedGoogle Scholar
  • 73 Järnerot G, Hertervig E, Friis-Liby I et al.. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.  Gastroenterology. 2005;  128(7) 1805-1811
    CrossrefPubMedGoogle Scholar
  • 74 Probert C S, Hearing S D, Schreiber S et al.. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial.  Gut. 2003;  52(7) 998-1002
    CrossrefPubMedGoogle Scholar
  • 75 Rutgeerts P, Sandborn W J, Feagan B G et al.. Infliximab for induction and maintenance therapy for ulcerative colitis.  N Engl J Med. 2005;  353(23) 2462-2476
    CrossrefPubMedGoogle Scholar
  • 76 Feagan B G, Reinisch W, Rutgeerts P et al.. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients.  Am J Gastroenterol. 2007;  102(4) 794-802
    CrossrefPubMedGoogle Scholar
  • 77 Aratari A, Papi C, Clemente V et al.. Colectomy rate in acute severe ulcerative colitis in the infliximab era.  Dig Liver Dis. 2008;  40(10) 821-826
    CrossrefPubMedGoogle Scholar
  • 78 Kariv R, Remzi F H, Lian L et al.. Preoperative colorectal neoplasia increases risk for pouch neoplasia in patients with restorative proctocolectomy.  Gastroenterology. 2010;  139(3) 806-812
    CrossrefPubMedGoogle Scholar
  • 79 D'Haens G, Baert F, van Assche G Belgian Inflammatory Bowel Disease Research Group et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.  Lancet. 2008;  371(9613) 660-667
    CrossrefPubMedGoogle Scholar
  • 80 Kane S V, Cohen R D, Aikens J E, Hanauer S B. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis.  Am J Gastroenterol. 2001;  96(10) 2929-2933
    CrossrefPubMedGoogle Scholar
  • 81 Cervený P, Bortlík M, Kubena A, Vlcek J, Lakatos P L, Lukás M. Nonadherence in inflammatory bowel disease: results of factor analysis.  Inflamm Bowel Dis. 2007;  13(10) 1244-1249
    CrossrefPubMedGoogle Scholar
  • 82 Sewitch M J, Abrahamowicz M, Barkun A et al.. Patient nonadherence to medication in inflammatory bowel disease.  Am J Gastroenterol. 2003;  98(7) 1535-1544
    CrossrefPubMedGoogle Scholar
  • 83 Bernal I, Domènech E, Garcia-Planella E et al.. Medication-taking behavior in a cohort of patients with inflammatory bowel disease.  Dig Dis Sci. 2006;  51(12) 2165-2169
    CrossrefPubMedGoogle Scholar
  • 84 Mackner L M, Crandall W V. Oral medication adherence in pediatric inflammatory bowel disease.  Inflamm Bowel Dis. 2005;  11(11) 1006-1012
    CrossrefPubMedGoogle Scholar
  • 85 Oliva-Hemker M M, Abadom V, Cuffari C, Thompson R E. Nonadherence with thiopurine immunomodulator and mesalamine medications in children with Crohn disease.  J Pediatr Gastroenterol Nutr. 2007;  44(2) 180-184
    CrossrefPubMedGoogle Scholar
  • 86 Wright S, Sanders D S, Lobo A J, Lennard L. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease.  Gut. 2004;  53(8) 1123-1128
    CrossrefPubMedGoogle Scholar
  • 87 Mantzaris G J, Sfakianakis M, Archavlis E et al.. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis.  Am J Gastroenterol. 2004;  99(6) 1122-1128
    CrossrefPubMedGoogle Scholar
  • 88 Kane S V, Aikens J E, Huo D, Hanauer S B. Medication adherence is associated with improved outcomes in patients with quiescent ulcerative colitis.  Am J Med. 2003;  114 39-43
    CrossrefPubMedGoogle Scholar
  • 89 Mahadevan U. Medical treatment of ulcerative colitis.  Clin Colon Rectal Surg. 2004;  17(1) 7-19
    Article in Thieme ConnectPubMedGoogle Scholar
  • 90 Navaneethan U, Shen B. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease.  Inflamm Bowel Dis. 2010;  16(9) 1598-1619 , [Epub ahead of print]
    CrossrefPubMedGoogle Scholar
  • 91 Farrell G C. Drug-Induced Liver Disease. 1st ed. Singapore; Churchill Livingstone 1994
    Google Scholar
  • 92 Mardini H E. Azathioprine-induced pancreatitis in Crohn's disease: a smoking gun or guilt by association.  Aliment Pharmacol Ther. 2005;  21(2) 195
    CrossrefPubMedGoogle Scholar
  • 93 Shale M, Kanfer E, Panaccione R, Ghosh S. Hepatosplenic T cell lymphoma in inflammatory bowel disease.  Gut. 2008;  57(12) 1639-1641
    CrossrefPubMedGoogle Scholar
  • 94 Lichtenstein G R, Feagan B, Cohen R D et al.. Risk factors for serious infections in patients receiving infliximab and other Crohn's disease therapies: TREAT registry data.  Gastroenterology. 2010;  38(Suppl 1) 475
    PubMedGoogle Scholar
  • 95 Selvasekar C R, Cima R R, Larson D W et al.. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis.  J Am Coll Surg. 2007;  204(5) 956-962 discussion 962-963
    CrossrefPubMedGoogle Scholar
  • 96 Mor I J, Vogel J D, da Luz Moreira A, Shen B, Hammel J, Remzi F H. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy.  Dis Colon Rectum. 2008;  51(8) 1202-1207 discussion 1207-1210
    CrossrefPubMedGoogle Scholar
  • 97 Chaparro M, Burgueno P, Flores E et al.. Efficacy and safety of infliximab rescue therapy after cyclosporine failure in patients with steroid-refractory ulcerative colitis: a multicenter study.  Gastroenterology. 2010;  38(Suppl) 688
    PubMedGoogle Scholar
  • 98 Järnerot G. Fertility, sterility, and pregnancy in chronic inflammatory bowel disease.  Scand J Gastroenterol. 1982;  17(1) 1-4
    CrossrefPubMedGoogle Scholar
  • 99 Narendranathan M, Sandler R S, Suchindran C M, Savitz D A. Male infertility in inflammatory bowel disease.  J Clin Gastroenterol. 1989;  11(4) 403-406
    CrossrefPubMedGoogle Scholar
  • 100 Toovey S, Hudson E, Hendry W F, Levi A J. Sulphasalazine and male infertility: reversibility and possible mechanism.  Gut. 1981;  22(6) 445-451
    CrossrefPubMedGoogle Scholar
  • 101 Moody G A, Probert C, Jayanthi V, Mayberry J F. The effects of chronic ill health and treatment with sulphasalazine on fertility amongst men and women with inflammatory bowel disease in Leicestershire.  Int J Colorectal Dis. 1997;  12(4) 220-224
    CrossrefPubMedGoogle Scholar
  • 102 Dejaco C MC, Mittermaier C, Reinisch W et al.. Azathioprine treatment and male fertility in inflammatory bowel disease.  Gastroenterology. 2001;  121(5) 1048-1053
    CrossrefPubMedGoogle Scholar
  • 103 Mahadevan U, Terdiman J P, Aron J, Jacobsohn S, Turek P. Infliximab and semen quality in men with inflammatory bowel disease.  Inflamm Bowel Dis. 2005;  11(4) 395-399
    CrossrefPubMedGoogle Scholar
  • 104 Dominitz J A, Young J C, Boyko E J. Outcomes of infants born to mothers with inflammatory bowel disease: a population-based cohort study.  Am J Gastroenterol. 2002;  97(3) 641-648
    CrossrefPubMedGoogle Scholar
  • 105 Nørgård B, Fonager K, Pedersen L, Jacobsen B A, Sørensen H T. Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy: a Danish cohort study.  Gut. 2003;  52(2) 243-247
    CrossrefPubMedGoogle Scholar
  • 106 Nørgård B, Pedersen L, Fonager K, Rasmussen S N, Sørensen H T. Azathioprine, mercaptopurine and birth outcome: a population-based cohort study.  Aliment Pharmacol Ther. 2003;  17(6) 827-834
    CrossrefPubMedGoogle Scholar
  • 107 Eaden J A, Abrams K R, Mayberry J F. The risk of colorectal cancer in ulcerative colitis: a meta-analysis.  Gut. 2001;  48(4) 526-535
    CrossrefPubMedGoogle Scholar
  • 108 Choi P M, Nugent F W, Schoetz Jr D J, Silverman M L, Haggitt R C. Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis.  Gastroenterology. 1993;  105(2) 418-424
    PubMedGoogle Scholar
  • 109 Lynch D A, Lobo A J, Sobala G M, Dixon M F, Axon A T. Failure of colonoscopic surveillance in ulcerative colitis.  Gut. 1993;  34(8) 1075-1080
    CrossrefPubMedGoogle Scholar
  • 110 Sonnenberg A, El-Serag H B. Economic aspects of endoscopic screening for intestinal precancerous conditions.  Gastrointest Endosc Clin N Am. 1997;  7(1) 165-184
    PubMedGoogle Scholar
  • 111 Collins Jr R H, Feldman M, Fordtran J S. Colon cancer, dysplasia, and surveillance in patients with ulcerative colitis. A critical review.  N Engl J Med. 1987;  316(26) 1654-1658
    CrossrefPubMedGoogle Scholar
  • 112 Provenzale D, Onken J. Surveillance issues in inflammatory bowel disease: ulcerative colitis.  J Clin Gastroenterol. 2001;  32(2) 99-105
    CrossrefPubMedGoogle Scholar
  • 113 Pinczowski D, Ekbom A, Baron J, Yuen J, Adami H O. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study.  Gastroenterology. 1994;  107(1) 117-120
    CrossrefPubMedGoogle Scholar
  • 114 Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case-control study.  Aliment Pharmacol Ther. 2000;  14(2) 145-153
    PubMedGoogle Scholar
  • 115 Velayos F S, Terdiman J P, Walsh J M. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies.  Am J Gastroenterol. 2005;  100(6) 1345-1353
    CrossrefPubMedGoogle Scholar
  • 116 Kornbluth A, Sachar D B. Practice Parameters Committee of the American College of Gastroenterology . Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee.  Am J Gastroenterol. 2010;  105(3) 501-523, quiz 524
    CrossrefPubMedGoogle Scholar
  • 117 Woolrich A J, DaSilva M D, Korelitz B I. Surveillance in the routine management of ulcerative colitis: the predictive value of low-grade dysplasia.  Gastroenterology. 1992;  103(2) 431-438
    PubMedGoogle Scholar
  • 118 Winawer S, Fletcher R, Rex D Gastrointestinal Consortium Panel et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence.  Gastroenterology. 2003;  124(2) 544-560
    CrossrefPubMedGoogle Scholar
  • 119 Camilleri-Brennan J, Steele R J. Objective assessment of quality of life following panproctocolectomy and ileostomy for ulcerative colitis.  Ann R Coll Surg Engl. 2001;  83(5) 321-324
    PubMedGoogle Scholar
  • 120 Carmon E, Keidar A, Ravid A, Goldman G, Rabau M. The correlation between quality of life and functional outcome in ulcerative colitis patients after proctocolectomy ileal pouch anal anastomosis.  Colorectal Dis. 2003;  5(3) 228-232
    CrossrefPubMedGoogle Scholar
  • 121 Fazio V W, O'Riordain M G, Lavery I C et al.. Long-term functional outcome and quality of life after stapled restorative proctocolectomy.  Ann Surg. 1999;  230(4) 575-584 discussion 584-586
    CrossrefPubMedGoogle Scholar
  • 122 Thirlby R C, Sobrino M A, Randall J B. The long-term benefit of surgery on health-related quality of life in patients with inflammatory bowel disease.  Arch Surg. 2001;  136(5) 521-527
    CrossrefPubMedGoogle Scholar
  • 123 Berndtsson I, Oresland T. Quality of life before and after proctocolectomy and IPAA in patients with ulcerative proctocolitis—a prospective study.  Colorectal Dis. 2003;  5(2) 173-179
    CrossrefPubMedGoogle Scholar
  • 124 Martin A, Dinca M, Leone L et al.. Quality of life after proctocolectomy and ileo-anal anastomosis for severe ulcerative colitis.  Am J Gastroenterol. 1998;  93(2) 166-169
    CrossrefPubMedGoogle Scholar
  • 125 Parks A G, Nicholls R J. Proctocolectomy without ileostomy for ulcerative colitis.  BMJ. 1978;  2(6130) 85-88
    CrossrefPubMedGoogle Scholar
  • 126 McLeod R S, Baxter N N. Quality of life of patients with inflammatory bowel disease after surgery.  World J Surg. 1998;  22(4) 375-381
    CrossrefPubMedGoogle Scholar

Bo ShenM.D. 

Digestive Disease Institute, Desk A31

Cleveland Clinic, 9500 Euclid Ave., Cleveland, OH 44195

Email: shenb@ccf.org

      >